To view or add a comment, sign in I appreciated the opportunity to be interviewed by Nick Paul Taylor for this BioSpace article discussing the FDAs recently published draft guidance, General Considerations for the Use of New Approach Methodologies in Drug Development. Historically, drug developers have often included in vitro NAM assay reports in regulatory submissions with limited explanatory context, resulting in minimal impact on the regulators safety assessment
While fast food does not "block" injectable GLP-1 drugs in a pharmacological sense, it can undermine treatment effectiveness and worsen tolerability
In the as-treated analysis median follow-up was 1 year [0-2] for GLP-1 RA users and 1 year [13] for users of DPP-4 inhibitors
If youre considering GLP-1 therapy, RXIV Infusions offers expert support, personalized dosing, and professional care to help you reach your health goals
Shroyer NF, Wallis D, Venken KJT, Bellen HJ, Zoghbi HY